A patient-derived subrenal capsule xenograft model can predict response to adjuvant therapy for cancers in the head of the pancreas

This SRCPCX model retains major histopathological and immunohistochemical characteristics of the original tumour and when a combination of measures is used, enables early assessment of tumour sensitivity to gemcitabine in pancreatic cancers.